AAAna Luisa Andrade-Oliveira

Ana Luisa Andrade-Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Luisa Andrade-Oliveira has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimized Plasmid Extraction Uncovers Novel and Mobilizable Plasmids in Staphylococcus nepalensis Sharing Antimicrobial Resistance Across Different Bacterial Genera

    by Ana Luisa Andrade-Oliveira, Francisco Prodocimi, Rosane Silva, Ciro César Rossi, Marcia Giambiagi-Demarval

    Plasmids are key vectors in the dissemination of antimicrobial resistance (AMR), often transcending species and genus boundaries through horizontal gene transfer. Staphylococcus nepalensis, typically regarded as a commensal species, has emerged as a potential reservoir of resistance genes. In this study, we optimized plasmid extraction protocols to enhance the recovery of low-copy plasmids and applied whole-genome sequencing to characterize plasmids from a S. nepalensis strain isolated from the oral microbiota of a healthy cat in Brazil. Plasmid-enriched extraction using the Qiagen miniprep kit, with an additional enzymatic lysis step, significantly improved assembly outcomes, enabling the recovery of four complete plasmids. Three of them carried mobilizable antimicrobial resistance genes (aadK, cat, and tetK), conferring resistance to streptomycin, chloramphenicol, and tetracycline, respectively. Comparative and phylogenetic analyses revealed a high sequence similarity between these plasmids and mobile elements found in diverse pathogenic and environmental bacteria, including Staphylococcus aureus, S. epidermidis, Enterococcus sp., and Pseudomonas aeruginosa, indicating plasmid circulation across bacterial genera. Additionally, one novel plasmid was identified, displaying limited similarity to any known sequence and suggesting the existence of uncharacterized plasmid lineages in commensal staphylococci. These findings highlight the underestimated role of S. nepalensis as a hidden reservoir of mobilizable resistance genes and reinforce the need to surveil non-pathogenic bacteria in AMR monitoring frameworks.

  • Discovery of phage CSF, a novel generalist bacteriophage targeting multidrug-resistant and potentially pathogenic Staphylococcus spp. and Mammaliicoccus spp.

    by Faizan Ahmad, Vitor Emanuel Lanes Viana, Rafael Reis de Rezende, Samuel Sathler Martuchelle, Anderson Souza Cabral, Ana Luisa Andrade-Oliveira, Isabella Monteiro Carvalho, Sandy de Almada Estanislau, Nohman Rasheed, Poliane Alfenas Zerbini, et al.

    Antimicrobial resistance is escalating among Staphylococcus species, which are major pathogens affecting both humans and animals. As therapeutic options continue to narrow, phage therapy is re-emerging as a promising strategy to combat resistant strains. In this study, we isolated from pig farm effluents a bacteriophage named CSF, infecting a Staphylococcus xylosus strain. The CSF phage demonstrated a broad host range, lysing mecA-positive, multidrug-resistant strains across nine species of the genera Staphylococcus and Mammaliicoccus. Notably, it also inhibited biofilm formation in strains that it could not infect directly, and this activity persisted at low virus concentrations and in combination with antibiotics. The phage maintained its lytic activity under extreme conditions of temperature, pH, and UV exposure, underscoring its resilience for practical use. Sequencing of the viral genome revealed that it is 140 kb in length and has a genetic composition consistent with a lytic lifestyle. Phylogenetic analysis showed that phage CSF is related to members of the family Herelleviridae that are found globally, suggesting a widespread distribution of related viral lineages. Importantly, the phage genome was found to lack bacterial virulence or antimicrobial resistance genes, suggesting its safety for biotechnological applications. Intergenomic comparisons indicated that CSF should be classified as a member of a new genus, expanding the known diversity of bacteriophages. These findings demonstrate potential of CSF for phage therapy and other biotechnological applications.